Loading
Ran the trials that made trastuzumab deruxtecan the first HER2-directed drug for lung cancer.
Bob T. Li is a Medical Oncologist in Thoracic Oncology and Physician Ambassador to China and Asia-Pacific at Memorial Sloan Kettering Cancer Center. He is known for leading DESTINY-Lung01, the trial that established trastuzumab deruxtecan as the first HER2-directed drug for HER2-mutant non-small-cell lung cancer, and for early studies of HER2-directed therapy in lung cancer. His selected paper reports trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer. He continues to work on antibody-drug conjugates and early drug development while leading MSK's partnerships across the Asia-Pacific region.
| Title | Journal | Year |
|---|---|---|
| Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer | New England Journal of Medicine | 2022 |
Shares DESTINY-Lung01, Trastuzumab deruxtecan.
Shares Memorial Sloan Kettering Cancer Center, Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC), Non-small-cell lung cancer.
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).